8-K: Coya Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

Coya Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and pipeline expansion.

Summary

• Coya Therapeutics reported its Q1 2025 financial results and provided a corporate update on May 13, 2025.
• The company had cash and cash equivalents of $35.5 million as of March 31, 2025.
• Research and development expenses for the quarter were $5.2 million, compared to $3.1 million in the same period last year.
• General and administrative expenses increased to $2.7 million from $2.4 million year-over-year.
• The net loss for the quarter was $7.3 million, compared to a net loss of $5.1 million in Q1 2024.
• Coya is advancing its COYA 302 program and anticipates an FDA IND submission in ALS during Q2 2025, followed by a Phase 2 clinical trial.
• The company is also planning to submit an FDA IND for FTD by the end of the year, with a Phase 2 clinical trial to follow.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported increased losses, it also highlighted progress in its clinical programs and upcoming milestones, suggesting potential for future growth.

Positives

• Coya Therapeutics has $35.5 million in cash and cash equivalents.
• The company is progressing with its COYA 302 program and expects to submit an IND for ALS in Q2 2025.
• Coya anticipates receiving $8.4 million in milestone payments from Dr. Reddys Laboratories upon IND acceptance and first patient dosing of COYA 302 in ALS.
• The company is expanding its pipeline with COYA 303 and COYA 301 in combination with GLP-1 Receptor Agonist for treatment of inflammatory diseases and filing of new intellectual property portfolio for the combination.
• Significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimers disease (AD).

Negatives

• Coya Therapeutics reported a net loss of $7.3 million for Q1 2025, compared to a net loss of $5.1 million for Q1 2024.
• Research and development expenses increased to $5.2 million for Q1 2025, compared to $3.1 million for Q1 2024.
• General and administrative expenses increased to $2.7 million for Q1 2025, compared to $2.4 million for Q1 2024.

Risks

• The company's forward-looking statements are subject to known and unknown risks, uncertainties, and assumptions.
• These risks include the success, cost, and timing of product candidate development activities and clinical trials.
• The company's ability to obtain funding for operations, development, and commercialization of product candidates is also a risk.
• The timing of and ability to obtain and maintain regulatory approvals is uncertain.
• The rate and degree of market acceptance and clinical utility of product candidates are not guaranteed.

Future Outlook

Coya Therapeutics anticipates submitting an IND for COYA 302 in ALS during Q2 2025 and for FTD by the end of the year, followed by Phase 2 clinical trials. The company also expects to publish data and release top-line clinical data for various trials throughout 2025.

Management Comments

• Coyas Chief Executive Officer Arun Swaminathan, Ph.D. commented, 'We believe the new data from the IIT trial in patients with FTD and the promising COYA 303 data showing the synergistic potential of low dose IL-2 and GLP-1 RAs has added to the growing evidence that our approach to address Treg dysfunction using combination approaches holds high promise and increases our confidence in the clinical outcomes for COYA-302 in the larger ALS and FTD studies that are planned.'
• Coyas Chief Medical Officer Dr. Fred Grossman commented, 'Coya 302 is advancing, and we anticipate is on track for an FDA IND submission in ALS during 2Q 2025 followed by the initiation of a controlled Phase 2 clinical trial. We are also planning to submit an FDA IND for FTD by the end of the year, which we intend to be followed by the initiation of a controlled Phase 2 clinical trial. Coya 302 is a pipeline within a product, and we continue to evaluate additional indications in severe neurodegenerative diseases that have no or inadequate current treatments.'

Industry Context

Coya Therapeutics is focused on developing treatments for neurodegenerative diseases by targeting regulatory T cell dysfunction. This approach aligns with the growing interest in immunomodulatory therapies for conditions like ALS, FTD, and Alzheimer's disease. The company's combination therapies, such as COYA 302, reflect a trend towards multi-targeted approaches in treating complex diseases.

Comparison to Industry Standards

• Coya's focus on Treg modulation places it among companies like Talaris Therapeutics and Sangamo Therapeutics, which are also exploring cell-based therapies for immune-related disorders.
• The development of COYA 302, a combination of low-dose IL-2 and CTLA4-Ig, is similar to efforts by other companies to enhance the efficacy of immunotherapies through synergistic combinations.
• The $35.5 million in cash and cash equivalents provides Coya with a runway comparable to other clinical-stage biotech companies of its size, allowing it to fund ongoing clinical trials and research activities.
• The increase in R&D expenses reflects the typical investment pattern for biotech companies advancing their lead programs towards clinical development, similar to companies like Amylyx Pharmaceuticals which invested heavily in the development of Relyvrio for ALS.

Stakeholder Impact

• Shareholders: The financial results and clinical progress will impact shareholder value.
• Employees: The advancement of clinical programs may create new opportunities for employees.
• Patients: Successful clinical trials could lead to new treatment options for patients with neurodegenerative diseases.
• Strategic Partner: Dr. Reddys Laboratories (DRL) will be impacted by the progress of COYA 302 in ALS.

Next Steps

• Submission of additional nonclinical data to support the start of the COYA 302 Phase 2 trial in patients with ALS expected by the end of Q2.
• Filing of IND for the COYA-302 Phase 2 trial in patients with FTD.
• Publication of data documenting role of inflammation in Parkinsons Disease.
• Publication of longitudinal data on Neurofilament Light Chain (NfL) and oxidative stress markers in patients with ALS.
• Report additional single cell proteomics data from the completed investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimers disease (AD).
• Top-line clinical data release for an investigator-initiated trial combining LD IL-2 + CTLA4-Ig in patients with FTD.

Key Dates

Keywords

Coya Therapeutics, Financial Results, COYA 302, Clinical Trials, Regulatory T cells, Tregs, ALS, FTD, R&D, IND